TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies

Author： Kuiperij H.   Abdo Wilson   Engelen Baziel   Schelhaas H.   Verbeek Marcel  

Publisher： Springer Publishing Company

ISSN： 0001-6322

Source： Acta Neuropathologica, Vol.120, Iss.6, 2010-12, pp. : 825-826

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Increased plasma amyloid-β 42 protein in sporadic inclusion body myositis

By Abdo Wilson  

Acta Neuropathologica, Vol. 118, Iss. 3, 2009-09 ,pp. : 429-431

Springer Publishing Company

Access to resources Recommend Favorite

Update on sporadic inclusion body myositis

By Hohlfeld Reinhard  

Brain, Vol. 134, Iss. 11, 2011-11 ,pp. : 3141-3145

Oxford University Press

Access to resources Recommend Favorite

Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis

By Sancricca Cristina  

Neurological Sciences, Vol. 32, Iss. 5, 2011-10 ,pp. : 841-847

Springer Publishing Company

Access to resources Recommend Favorite

Long-term observational study of sporadic inclusion body myositis

By Benveniste Olivier  

Brain, Vol. 134, Iss. 11, 2011-11 ,pp. : 3176-3184

Oxford University Press

Access to resources Recommend Favorite

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

By Nogalska Anna  

Acta Neuropathologica, Vol. 118, Iss. 3, 2009-09 ,pp. : 407-413

Springer Publishing Company

Access to resources Recommend Favorite